NEW YORK, May 3, 2013 (GLOBE NEWSWIRE) -- Veteran business journalist Carmen Roberts joins Justin Gover, CEO, GW Pharmaceuticals [GWPH] to discuss the company's industry, strategy, financials and positioning.
Click here to view video:
Justin Gover, CEO:
Justin Gover has served as Chief Executive Officer since January 1999. He has 17 years experience in the pharmaceutical industry.
As Chief Executive Officer, he has been the lead executive responsible for the running of the company's operations, as well as in leading equity financings and business development activities.
Prior to joining GW Pharmaceuticals, Mr. Gover was Head of Corporate Affairs at Ethical Holdings plc from 1995 to 1997 where he was responsible for the company's strategic corporate activities, including mergers and acquisitions, strategic investments, equity financings and investor relations since the company's inception.
Mr. Gover holds an M.B.A. from INSEAD and a BSc. (Hons) from Bristol University.
About GW Pharmaceuticals:
GW Pharmaceuticals was founded in 1998 and listed on AIM, a market of the London Stock Exchange, in June 2001. GW is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. The Group's lead programme is the development of a product portfolio of cannabinoid prescription medicines, including Sativex® Oromucosal Spray, to meet patient needs in a wide range of therapeutic indications.
For more information on the opportunity to have your CEO discuss your company, please call NASDAQ CEO Signature Series, 978/461-3141.
Source: NASDAQ CEO Signature Series;GW Pharmaceuticals